People · Operator
Named in public records as an officer, director or promoter · active 2009–2012 · Other, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Myoscience, Inc | — | Other | Series B | $122.6M | $83.1M | 2012 |
| Sebacia, Inc. | — | Other Health Care | Series B | $71.2M | $221.5M | 2010 |
| Cellutions Inc | — | Biotechnology | Pre-Seed | $1.0M | $55.2M | 2009 |
Thomas Weldon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Weldon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Anthony Lando | 3 | 6 |
| Charles Larsen | 2 | 7 |
| Steven Waite | 2 | 4 |
| Gordon Wyatt | 2 | 2 |
| Thomas D. Weldon | 2 | 2 |
| Richard Ferrari | 1 | 15 |
| Robert Grant | 1 | 12 |
| Ryan Schwarz | 1 | 7 |
| James Garvey | 1 | 6 |
| Kevin Wasserstein | 1 | 5 |
| Brian Farley | 1 | 5 |
| Richard M. Ferrari | 1 | 5 |
| Cary . Vance | 1 | 4 |
| Jesse Treu | 1 | 4 |
| Clint Carnell | 1 | 4 |
| Jan Pensaert | 1 | 3 |
| Rudi Marien | 1 | 3 |
| Thomas E. Hancock | 1 | 3 |
| Jon Serbousek | 1 | 3 |
| John Allison | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.